30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)

30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)
Lung Cancer
PD-L1/2 expression (IHC test) and anti-PD-L1/2 therapy have been written in the NCCNNSCLC 2017V1 edition of the guidelines. While PD-L1/2 expression (upregulation) is enabled by PD-L1/2 gene amplification (9p24.1), the two are positively correlated.
Lymphoma
A recurrent genetic abnormality in nodular sclerosing Hodgkin's lymphoma when the 9p24.1 region is amplified. The PD-L1 and PD-L2 genes encoding PD-1 ligand proteins (also known as CD274 and PDCD1LG2, respectively) in this region are important target genes in the 9p24.1 region.PD-L1(9p24)/CSP9 Gene Amplification Probe Reagents.